Trial Details
ACTIVE_NOT_RECRUITINGBasic Information
| Clinical ID | c1766 |
|---|---|
| Identifier | NCT04524611 |
| Trial Title | Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn's Disease (CD) |
| Interventions | DRUG: Risankizumab|DRUG: Risankizumab|DRUG: Ustekinumab|DRUG: Ustekinumab |
Participant Information
| Sponsor | AbbVie |
|---|---|
| City | Chandler |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2020-09-30 |
|---|---|
| Primary Completion Date | 2028-02 |
| Completion Date | 2028-02 |